SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Management of DAA Failures - Gregory T. Everson, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Obstacles to Treatment: Renal Disease, Ribavirin, DDIs - Michael Charlton, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Post-LT Renal Failure and HCV Rx - Peter Ferenci, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Use of HCV+ Donor Grafts - Didier Samuel, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016What Are the Treatment Options? - Maria Londoño, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Achieving SVR in CTP C – MELD Purgatory - Christophe Duvoux, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016When to Treat HCV in a Waiting List Patient? - Stefano Fagiuoli, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016What Are the Treatment Options? - Xavier Forns, MDView Slideset
NTNorah TerraultMD, MPH, FAASLDSlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Is Treatment Cost-effective? - Kosh Agarwal, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Treatment Experienced GT3 patient with Cirrhosis - Geoffrey McCaughan, MD, PhDView Slideset
NTNorah TerraultMD, MPH, FAASLDSlidesetViral Hepatitis and Liver DiseaseOptimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016Who Should We Treat? What is the “Point-of-No-Return”? - Norah Terrault, MD, MPH, FAASLDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Viral Hepatitis Elimination Meeting (IVHEM) 2017Medicines Patent Pool’s approach to scale up access to HIV and HCV treatment- Esteban BurroneView Slideset
